PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
14.27%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 2.91%. Joel Greenblatt would investigate if growth quality matches quantity.
15.53%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 1.47%. Jim Chanos would check for structural cost disadvantages.
9.27%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 2.60%. Joel Greenblatt would investigate competitive advantages.
-4.38%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.36%
Other expenses change of 24.36% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.54%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 4.88%. Mohnish Pabrai would examine discipline.
13.57%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 4.76%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
4.66%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.40%. Jim Chanos would check for overinvestment.
21.08%
EBITDA change of 21.08% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
5.96%
Margin change of 5.96% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
29.33%
Income change of 29.33% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
13.18%
Margin change of 13.18% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-143.64%
Other expenses reduction while Medical - Pharmaceuticals median is -10.60%. Seth Klarman would investigate advantages.
16.83%
Income change of 16.83% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
2.24%
Margin change of 2.24% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-14.44%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
31.60%
Income change of 31.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
15.17%
Margin change of 15.17% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
31.60%
EPS change of 31.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
31.60%
Diluted EPS change of 31.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.